Table 1.
Phenotypic and genotypic characteristics of OXA-type carbapenemase-producing clinical isolates and transconjugants
| Straina | Hospital | Yr | β-Lactamase(s) | Antimicrobial resistance profile | MIC (mg/liter)e |
PFGE type | |
|---|---|---|---|---|---|---|---|
| IPM | MPM | ||||||
| E. coli 84/08 | A | 2008 | OXA-162, TEM-1 | AMP FOX GEN CMP OTE CIP SXT | 8 | 16 | 1 |
| R. ornithinolytica 215/09b | A | 2009 | OXA-162, TEM-1, OXA-1, SHV-5 | AMP CTX CAZ KAN CMP CIP | 4 | 4 | 2 |
| C. freundii 216/09b | A | 2009 | OXA-162, SHV-5 | AMP FOX CTX CAZ GEN CMP | 2 | 2 | 3 |
| E. coli 131/08 | B | 2008 | OXA-48, TEM-1, OXA-1 | AMP GEN CMP OTE SXT | 32 | 32 | 4 |
| K. pneumoniae | |||||||
| 229/09 | C | 2009 | OXA-48, TEM-1, OXA-9, SHV-11, CTX-M-15 | AMP FOX CTX CAZ GEN KAN AMK CIP | >32 | >32 | 5 |
| 238/09 | C | 2009 | OXA-48, TEM-1, OXA-9, SHV-11, CTX-M-15 | AMP FOX CTX CAZ GEN KAN AMK CIP | >32 | >32 | 5 |
| 239/09 | C | 2009 | OXA-48, TEM-1, OXA-9, SHV-11, CTX-M-15 | AMP FOX CTX CAZ GEN KAN AMK CIP | >32 | >32 | 5 |
| 16/10 | D | 2010 | OXA-48, TEM-1, OXA-9, SHV-11, CTX-M-15 | AMP FOX CTX CAZ GEN KAN AMK CIP | 32 | >32 | 5 |
| E. cloacae 1/10 | E | 2010 | OXA-48, TEM-1, CTX-M-15 | AMP FOX CTX CAZ GEN KAN CMP CIP SXT | 4 | 8 | 6 |
| E. coli J53 | |||||||
| Tc 84/08 | OXA-162, TEM-1 | AMP GEN OTE SXT | 0.25 | 1 | |||
| Tc 131/08 | OXA-48, TEM-1 | AMP GEN CMP | 0.25 | 0.5 | |||
| Tcc | OXA-48 or OXA-162 | AMP | 1 | 1 | |||
| Rcd | ≤0.063 | ≤0.063 | |||||
a
Tc, transconjugant.
b
Isolates from the same patient.
c
Characteristics of transconjugants Tc 215/09, Tc 216/09, Tc 229/09, Tc 238/09, Tc 239/09, Tc 16/10, and Tc 1/10.
d
Recipient E. coli J53 resistant to sodium azide.
e
Determined by Etest. AMP, ampicillin; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; GEN, gentamicin; KAN, kanamycin; AMK, amikacin; CMP, chloramphenicol; OTE, oxytetracycline, CIP, ciprofloxacin; SXT, sulfamethoxazole-trimethoprim; IPM; imipenem; MPM, meropenem.